Eris Lifesciences forms JV with MJ Biopharm to enter India's insulin segment - BusinessToday
Diabetes Tips, News & Articles
Eris will now extend its product offering to insulins and GLP1 agonists. These categories comprise 61 per cent of the anti-diabetes market in the USA, ...
Note: This news content is auto-generated from a syndicated feed.
If you have a family history of diabetes you could be at risk, get tested now! Book Diabetes test online
Eris will now extend its product offering to insulins and GLP1 agonists. These categories comprise 61 per cent of the anti-diabetes market in the USA, ...
Eris will now extend its product offering to insulins and GLP1 agonists. These categories comprise 61 per cent of the anti-diabetes market in the USA, ...
Read moreNote: This news content is auto-generated from a syndicated feed.
If you have a family history of diabetes you could be at risk, get tested now! Book Diabetes test online